- Series 2017A revenue bonds
- Series 2017B revenue bonds
- Series 2017C revenue bonds
- Series 2015A revenue bonds
- Series 2011A revenue bonds
- Series 2009A revenue bonds
The outlook is positive, reflecting the cancer center’s strengthening balance sheet in fiscal year 2016 and the subsequent liquidation of a portion of its stock in Seattle-based Juno Therapeutics, which bolstered the cancer center’s cash and investments during the past two fiscal years.
More articles on healthcare finance:
S&P places MetroHealth System’s ‘A-‘ bonds on CreditWatch
S&P lowers North Oaks Health System’s rating to ‘BB+’ on select bonds
Fitch assigns ‘AA-‘ rating to University Medical Center of El Paso’s bonds
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.